Levi & Korsinsky reminds Regeneron investors of upcoming class action lawsuit

Levi & Korsinsky is alerting investors of Regeneron Pharmaceuticals, Inc. about an impending class-action lawsuit. The lawsuit has a lead plaintiff deadline of March 10, 2025. Investors who purchased or otherwise acquired Regeneron stock between May 21, 2013, and October 19, 2017, may be eligible to participate in the class-action lawsuit.

The lawsuit alleges that Regeneron made false and misleading statements to investors during the specified period. The company is accused of failing to disclose information related to the improper allocation of sales volumes between wholesalers. This allegedly led to an artificial inflation of the company’s reported revenue, causing harm to investors who relied on this misrepresented data in their investment decisions.

Investors who suffered financial losses as a result of investing in Regeneron during the mentioned period are encouraged to join the class-action lawsuit before the lead plaintiff deadline of March 10, 2025. Those interested in participating in the lawsuit should contact Levi & Korsinsky to discuss their legal rights. It is crucial for affected investors to take action promptly to ensure their eligibility to participate in the lawsuit.

Levi & Korsinsky is a leading law firm representing investors and consumers in various legal matters, including securities litigation. The firm has a successful track record of recovering significant damages for its clients who have been harmed by corporate wrongdoing. With their expertise and dedication to advocating for investors’ rights, Levi & Korsinsky provides essential legal representation for those seeking justice against fraudulent practices by companies like Regeneron Pharmaceuticals, Inc.

Investors who have suffered losses due to the alleged misconduct by Regeneron are encouraged to contact Levi & Korsinsky promptly. By joining the class-action lawsuit, affected investors have the opportunity to seek compensation for their financial losses caused by the alleged misleading statements and omissions made by the company. The deadline to become a lead plaintiff in this lawsuit is March 10, 2025, so investors should act quickly to protect their rights and potentially recover damages.

It is vital for investors who believe they were harmed by Regeneron’s actions to seek legal counsel and explore their options for participating in the class-action lawsuit. Levi & Korsinsky stands ready to assist investors in pursuing justice and holding accountable companies that engage in fraudulent practices. By coming forward to join the lawsuit, affected investors can contribute to seeking accountability and recovering losses resulting from the alleged misconduct of Regeneron Pharmaceuticals, Inc.